Discounted Cash Flow (DCF) Analysis Levered

Knight Therapeutics Inc. (GUD.TO)

$4.85

-0.03 (-0.61%)
All numbers are in Millions, Currency in USD
Stock DCF: 1,030.04 | 4.85 | undervalue

Free Cash Flow

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue 8.6312.5047.46199.52243.48649.411,732.104,619.8612,322.1232,865.63
Revenue (%)
Operating Cash Flow 23.46-5.744.60-12.2144.62321.67857.952,288.326,103.4316,279.10
Operating Cash Flow (%)
Capital Expenditure -0.13-3.87-2.95-20.67-224.18-183.24-488.73-1,303.55-3,476.83-9,273.43
Capital Expenditure (%)
Free Cash Flow 23.33-9.611.65-32.87-179.57138.43369.22984.782,626.607,005.68

Weighted Average Cost Of Capital

Share price $ 4.85
Beta 0.523
Diluted Shares Outstanding 124.52
Cost of Debt
Tax Rate -134.30
After-tax Cost of Debt 8.83%
Risk-Free Rate
Market Risk Premium
Cost of Equity 6.213
Total Debt 40.96
Total Equity 603.93
Total Capital 644.89
Debt Weighting 6.35
Equity Weighting 93.65
Wacc

Build Up Free Cash Flow

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue 8.6312.5047.46199.52243.48649.411,732.104,619.8612,322.1232,865.63
Operating Cash Flow 23.46-5.744.60-12.2144.62321.67857.952,288.326,103.4316,279.10
Capital Expenditure -0.13-3.87-2.95-20.67-224.18-183.24-488.73-1,303.55-3,476.83-9,273.43
Free Cash Flow 23.33-9.611.65-32.87-179.57138.43369.22984.782,626.607,005.68
WACC
PV LFCF 130.13326.26818.012,050.945,142.21
SUM PV LFCF 8,467.55

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 6.38
Free cash flow (t + 1) 7,145.79
Terminal Value 163,145.87
Present Value of Terminal Value 119,750.18

Intrinsic Value

Enterprise Value 128,217.72
Net Debt -45.01
Equity Value 128,262.73
Shares Outstanding 124.52
Equity Value Per Share 1,030.04